RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Chronic Myelomonocytic Leukaemia: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Rare Glimpse into Splenic Histopathology, Especially Megakaryocyte Dyspoiesis, in Chronic Myelomonocytic Leukemia
T. Devi et al., Indian Journal of Hematology and Blood Transfusion (17 October 2026)
https://doi.org/10.1007/s12288-026-02607-0
- 2.
[Recommendations of the Groupe Francophone des Myélodysplasies (GFM) - Diagnostic approach and management of myelodysplastic syndromes, chronic myelomonocytic leukemias, and VEXAS syndrome].
Park Sophie et al., Bulletin du cancer (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42881104/
- 3.
A phase 1b/2 study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.
Brunner Andrew M et al., Blood advances (13 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42379235/
- 4.
Auto-immune diseases associated with myelodysplastic syndrome and chronic myelomonocytic leukemia do not impact allogenic transplantation outcomes.
Ruggiu Mathilde et al., Bone marrow transplantation (6 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42839029/
- 5.
Risk-Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Patients.
Alsugair Ali et al., American journal of hematology (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42499183/
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
NCT05636514 · Recruiting · Phase 1 · Clinical Hub for Interventional Research (CHOIR)
Ages 18 and over
https://clinicaltrials.gov/study/NCT05636514
- 2.
Study to Evaluate the Safety and Tolerability of EP0042
NCT04581512 · Recruiting · Phase 1 / Phase 2 · Ellipses Pharma
Ages 18 and over
https://clinicaltrials.gov/study/NCT04581512
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Chronic Myelomonocytic Leukaemia
Chronic myelomonocytic leukaemia is a rare cancer of the blood and bone marrow that mainly affects older adults. It causes a persistently high number of a type of white blood cell called monocytes, and can lead to anaemia, infections, bruising and an enlarged spleen. Treatment ranges from careful monitoring to medicines that act on the bone marrow. Stem cell transplant is an option for some people.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Common Questions
What is Chronic Myelomonocytic Leukaemia?
Chronic myelomonocytic leukaemia is a rare cancer of the blood and bone marrow that mainly affects older adults. It causes a persistently high number of a type of white blood cell called monocytes, and can lead to anaemia, infections, bruising and an enlarged spleen. Treatment ranges from careful monitoring to medicines that act on the bone marrow. Stem cell transplant is an option for some people.
How many clinical trials are available for Chronic Myelomonocytic Leukaemia?
RareWays currently indexes 282 clinical trials for Chronic Myelomonocytic Leukaemia, of which 51 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Chronic Myelomonocytic Leukaemia come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Chronic Myelomonocytic Leukaemia.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.